These conditions may have synergistically affected the severity of neurological symptoms (e.g., urinary retention, headache) and responses to anti-infection/immunosuppressive therapy, complicating efforts to isolate the independent pathogenic role of GFAP autoimmunity from the effects of metabolic dysfunction or infection-induced inflammation. The gene discussed is GFAP; the disease is Autoimmunity.